IGC Pharma, Inc.

IGC Pharma, Inc. is a U.S.-based clinical-stage pharmaceutical company focused on Alzheimer’s disease and related neurodegenerative conditions. Its lead program, IGC-AD1, is in Phase 2 testing for agitation in Alzheimer’s dementia, while the company also sells a small portfolio of white-label, private-label, and branded wellness products through its Life Sciences segment.

−537,2 %

48,7 %

−560,3 %

−5,5 %

1.28

0.68

— IGC Pharma, Inc.
%
Clinical-stage therapeutics0% Investigational Alzheimer’s and neurodegenerative disease drug candidates in preclinical and Phase 2 development.
Life Sciences consumer and white-label products100% Manufactured formulations, white-label products, and branded wellness items sold commercially.
Research and development services0% Internal clinical development, trial operations, and related scientific work supporting pipeline advancement.

IGC Pharma sells primarily to commercial buyers of manufactured wellness and formulation products, while its core...

  • Commercial formulation customersprimary

    Buy white-label and private-label manufactured products for resale or distribution.

  • Branded wellness consumerssecondary

    Purchase holistic health and branded products through retail and online channels.

  • Alzheimer’s patients and caregiversprimary

    The end market for IGC-AD1 and future neurodegenerative therapies aimed at symptom relief.

  • Healthcare partners and licenseesemerging

    Potential collaborators that may help fund, develop, or commercialize pipeline assets.

IGC Pharma is headquartered in the United States and manufactures products in Vancouver, Washington, which is important...

  • •Headquartered in the United States
  • •Manufacturing and fulfillment tied to Vancouver, Washington
  • •U.S. FDA oversight is central to pipeline commercialization
  • •No country-level revenue split was disclosed in the excerpts
  • •Facility disposition temporarily reduced production and shipments

IGC Pharma is prioritizing advancement of IGC-AD1 through Phase 2 clinical development while building a broader...

01
Complete Phase 2 development of IGC-AD1short-term

The lead asset is the main driver of future value and clinical validation.

02
Expand the Alzheimer’s pipelinemedium-term

A broader pipeline reduces single-asset dependence and improves partnering potential.

03
Preserve liquidity and access to capitalshort-term

The company remains loss-making and needs funding to sustain R&D and trials.

04
Use internal execution to lower trial costsmedium-term

Lower per-patient trial costs improve capital efficiency and extend runway.

IGC Pharma faces the typical risks of a clinical-stage biotech company: trial failure, regulatory delay, and the...

high

Lead program may fail in clinical development

IGC-AD1 is still in Phase 2, so efficacy or safety issues could stop commercialization.

Scope
IGC-AD1 and broader Alzheimer’s pipeline
Materiality
high
high

Dependence on external financing

The company has recurring losses and limited cash, so it relies on equity raises and other funding.

Scope
Operations, R&D, and working capital
Materiality
high
high

Competitive pressure in Alzheimer’s therapeutics

Larger pharmaceutical companies have more capital, development capacity, and commercialization reach.

Scope
Alzheimer’s agitation treatment market
Materiality
high
medium

Customer and supplier concentration

A few customers and suppliers account for a meaningful share of activity, increasing disruption risk.

Scope
Life Sciences commercial business
Materiality
medium
medium

Digital asset treasury volatility

Mark-to-market changes on ETP holdings can affect reported earnings and liquidity perception.

Scope
Treasury management
Materiality
medium
Revenue recognition under ASC 606
Affects quarterly revenue and gross margin comparability
Digital asset fair-value accounting
Can introduce non-operating volatility in net loss
Impairment of long-lived assets
Can materially reduce operating results in a period
Stock-based compensation and warrant valuation
Affects operating expenses and shareholder dilution analysis

Gain Therapeutics, Inc.

GANX · Pharmaceutical Preparations

Dogwood Therapeutics, Inc.

DWTX · Pharmaceutical Preparations

Voyager Therapeutics, Inc.

VYGR · Biological Products, (No Diagnostic Substances)

Coya Therapeutics, Inc.

COYA · Pharmaceutical Preparations

BioXcel Therapeutics, Inc.

BTAI · Pharmaceutical Preparations

IMAC Holdings, Inc.

BACK · Services-Specialty Outpatient Facilities, NEC

: 28/04/2026